<DOC>
	<DOCNO>NCT00576251</DOCNO>
	<brief_summary>The purpose study describe difference efficacy TOBRADEX Ophthalmic Suspension Tobramycin 0.3 % /Dexamethasone 0.05 % Ophthalmic Suspension treatment ocular inflammation infection associate blepharaconjunctivitis</brief_summary>
	<brief_title>TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3 % /Dexamethasone 0.05 % Ophthalmic Suspension</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Ocular inflammation associate blepharaconjunctivitis ocular allergy ocular disorder would preclude safe administration test article</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Ocular inflammation</keyword>
	<keyword>blepharaconjunctivitis</keyword>
</DOC>